A
Andra Curcean
Researcher at Institute of Cancer Research
Publications - 9
Citations - 446
Andra Curcean is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Magnetic resonance imaging & Prostate cancer. The author has an hindex of 3, co-authored 7 publications receiving 221 citations. Previous affiliations of Andra Curcean include The Royal Marsden NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo,Nuria Porta,Diletta Bianchini,Ursula McGovern,Tony Elliott,Robert Jones,Isabel Syndikus,Christy Ralph,Suneil Jain,Mohini Varughese,Omi Parikh,Simon J. Crabb,Angus Robinson,Duncan B. McLaren,A. Birtle,Jacob Tanguay,Susana Miranda,Ines Figueiredo,George Seed,Claudia Bertan,Penny Flohr,Berni Ebbs,Pasquale Rescigno,Gemma Fowler,Ana Ferreira,Ruth Riisnaes,Rita Pereira,Andra Curcean,Robert Chandler,Matthew Clarke,Bora Gurel,Mateus Crespo,Daniel Nava Rodrigues,Shahneen Sandhu,Aude Espinasse,Peter Chatfield,Nina Tunariu,Wei Yuan,Emma Hall,Suzanne Carreira,Johann S. de Bono +40 more
TL;DR: The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in metastatic castration-resistant prostate cancer by recruiting participants from 17 UK hospitals and following follow-up for a period of 24·8 months.
Journal ArticleDOI
What’s New for Clinical Whole-body MRI (WB-MRI) in the 21st Century
Nina Tunariu,Matthew D. Blackledge,Christina Messiou,Giuseppe Petralia,Anwar R. Padhani,Sebastian Curcean,Andra Curcean,Andra Curcean,Dow-Mu Koh +8 more
TL;DR: Whole body MRI can be used to track disease evolution and monitor response heterogeneity in patients with cancer, and opportunities to combine WB-MRI with molecular imaging on PET-MRI systems to harness the strengths of hybrid imaging are seen.
Journal ArticleDOI
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
Dionysis Papadatos-Pastos,Wei Yuan,Abhijit Ricky Pal,Mateus Crespo,Ana Ferreira,Bora Gurel,Toby Prout,Malaka Ameratunga,Maxime Chénard-Poirier,Andra Curcean,Claudia Bertan,C Baker,Susana Miranda,Nahal Masrour,Wentin Chen,Rita Pereira,Ines Figueiredo,Ricardo Morilla,Benjamin Jenkins,Anna Zachariou,Ruth Riisnaes,Mona Parmar,Alison Turner,Suzanne Carreira,Christina Yap,Robert H. Brown,Nina Tunariu,Udai Banerji,Juanita Lopez,Johann S. de Bono,Anna Minchom +30 more
TL;DR: Reversal of previous resistance to immune checkpoint inhibitors is demonstrated and guadecitabine in combination with pembrolizumab is tolerable with biological and anticancer activity.
Journal ArticleDOI
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials
Angelika Terbuch,Angelika Terbuch,Crescens Tiu,Irene Moreno Candilejo,Mariana Scaranti,Andra Curcean,Dan Bar,Miriam Estevez Timon,Malaka Ameratunga,Malaka Ameratunga,Joo Ern Ang,Joo Ern Ang,Jonathan Ratoff,Jonathan Ratoff,Anna Minchom,Udai Banerji,Johann S. de Bono,Nina Tunariu,Juanita Lopez +18 more
TL;DR: DILD in early-phase clinical trials is a toxicity of variable onset, with diverse clinical and radiological findings, and improve with treatment interruption, which should be considered early.
Journal ArticleDOI
Accelerating Whole-Body Diffusion-weighted MRI with Deep Learning-based Denoising Image Filters.
Konstantinos Zormpas-Petridis,Nina Tunariu,Andra Curcean,Christina Messiou,Sebastian Curcean,David J. Collins,Julie C Hughes,Yann Jamin,Dow-Mu Koh,Matthew D. Blackledge +9 more
TL;DR: A deep learning–based denoising image filter (DNIF) model was developed to improve the image quality of subsampled images to reduce whole-body diffusion-weighted MRI (WBDWI) acquisition times and visually improved the quality of NOA1 images in all test patients.